Newsroom

Sorted by: Latest

-

Akamis Bio to Present Data from a Phase 1 Study of NG-348 in Patients with Advanced Epithelial Tumors at SITC 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akamis Bio, a clinical-stage oncology company working to advance the standard of care in colorectal cancer, today announced an upcoming poster presentation of first-in-human clinical data from a Phase 1 study of NG-348 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2026, being held from November 4–8, in Phoenix, Arizona. NG-348 is an intravenously delivered oncolytic immunotherapy designed to drive intratumoral expression of two membrane-boun...
-

SharkNinja Unveils Ninja Luxe™ Café Pro Espresso Machine by Jonathan Adler

NEEDHAM, Mass.--(BUSINESS WIRE)--SharkNinja, Inc., a global product design and technology company and makers of the #1 espresso machine in the U.S.¹, today announced the Ninja Luxe™ Café Pro Espresso Machine by Jonathan Adler. This exclusive limited-edition collaboration brings together Ninja’s proven espresso engineering with Adler’s signature aesthetic of Modern American Glamour. The collaboration marks a new expression of the Ninja Luxe™ Café collection, expanding beyond color into designer-...
-

Straive and Anthropic Partner to Advance Responsible Enterprise AI

NEW YORK--(BUSINESS WIRE)--Straive today announced a partnership with Anthropic to help enterprises build, deploy, and run AI responsibly across business workflows....
-

A2 Biotherapeutics Presents Updated Safety and Efficacy Data from EVEREST-2 and DENALI-1 Clinical Studies during 2026 Annual Meeting of the Society for Immunotherapy of Cancer

PHOENIX--(BUSINESS WIRE)--A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage immunotherapy company developing first-in-class logic-gated cell therapies for solid tumors, today announced the presentation of updated safety and efficacy data from the EVEREST-2 (NCT06051695) and DENALI-1 (NCT06682793) clinical studies. The data includes updates on the first reported case of complete response (CR) to CAR T-cell therapy in a patient with non-small cell lung cancer (NSCLC) in the EVEREST-2 study, as...
-

Navan Selected by Ingersoll Rand to Modernize Global Business Travel

PALO ALTO, Calif.--(BUSINESS WIRE)--Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Ingersoll Rand has selected Navan’s platform for its global travel management program.As a global manufacturer serving customers in more than 100 countries, Ingersoll Rand is focused on providing employees with efficient tools that support productivity while strengthening visibility and governance across enterprise operations.With Navan, Ingersoll Rand is exp...
-

Ameriprise Financial Chief Financial Officer to Present at the 2026 BMO Financials Conference

MINNEAPOLIS--(BUSINESS WIRE)--Ameriprise Financial, Inc. (NYSE: AMP) today announced that Walter S. Berman, executive vice president and chief financial officer, is scheduled to speak about the company’s business and strategy at the 2026 BMO Financials Conference on Tuesday, November 10, 2026 at approximately 11:00 am ET. A live webcast of the fireside chat will be available at the event website at https://app.webinar.net/LWXnqkXodjA or via the Ameriprise Financial Investor Relations website at...
-

Guava Lands $12.5 Million to Tackle Voice AI’s Real-world Growing Pains

LOS ANGELES--(BUSINESS WIRE)--Guava, a new developer platform for building voice agents, today announced $12.5 million in seed financing led by Acrew Capital, with participation from Flourish Ventures, WillowTree Ventures, Clocktower Ventures, and Guava pre-seed investor Commerce Ventures. The fresh capital will support continued model and product development and kick-start Guava’s go-to-market team serving enterprises and business process outsourcers. Guava’s first public model, Daytona, launc...
-

NATIXIS UK Regulatory Announcement: Form 8.3 Spire Healthcare Group plc

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...
-

Starfighters Space to Host Investor Update on Nov. 6

KENNEDY SPACE CENTER, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. ("Starfighters" or the "Company") (NYSE American: FJET), the space company operating the world's only commercial fleet of flight-ready Mach 2+ supersonic aircraft, today announced that CEO Tim Franta will host a live briefing on Friday, Nov. 6, 2026, at 4p.m. ET. During the briefing, Franta will provide an update on the Company’s operations and outlook, including: Progress on the Wind Tunnel in the Sky™ reusable Mach 2+ airbo...
-

Outdoor Voices® Accelerates Global Expansion in the United Kingdom and Europe

NEW YORK & LONDON--(BUSINESS WIRE)--Outdoor Voices, the American active-lifestyle brand known for its recreation-first approach to movement and community, today announced a strategic partnership with Focus Brands to expand across the United Kingdom and European Union. The partnership represents another significant milestone in Outdoor Voices’ international growth strategy under Consortium Brand Partners (CBP), following the brand’s recently announced expansion into Korea, China and Southeast As...